The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
6 reports and counting
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Biotech Kinaset Therapeutics secures $103 million Series B for inhalable pan-JAK inhibitor treating severe asthma.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Annexon Biosciences raises $125M Series D at $750M valuation
Annexon Biosciences raises $125M in Series D at $750M valuation. Classical complement pathway inhibitors...
Crystalys Therapeutics Raises $205M Series A to Transform Biotech
Crystalys Therapeutics has secured $205M Series A in funding to accelerate growth and innovation in the biotech sector. Clinical-stage biopharmaceutical company developing next-generation oral URAT1 inhibitor dotinurad for the treatment of ...
Annexon Biosciences Raises $125M in Series D
Annexon Biosciences, a Biotech company based in 180 Kimball Way, South San Francisco, CA 94080, has raised $125M in Series D at a $750M valuation led by GV, Alta Partners, Omega Funds, Cowen Healthcare Investments, Redmile Group.
Braveheart Bio Raises $185 million in Series A
Braveheart Bio, a Biotechnology company based in San Francisco CA, has raised $185 million in Series A at a Undisclosed led by Andreessen Horowitz.
Showing 6 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.